Ocera Therapeutics (OCRX) Receives Daily News Impact Score of 0.04
Headlines about Ocera Therapeutics (NASDAQ:OCRX) have been trending somewhat positive on Monday, Accern reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ocera Therapeutics earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.4761500028744 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of research firms recently issued reports on OCRX. Zacks Investment Research downgraded shares of Ocera Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 8th. HC Wainwright downgraded shares of Ocera Therapeutics from a “buy” rating to a “neutral” rating and set a $1.75 target price for the company. in a research report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. Ocera Therapeutics presently has a consensus rating of “Hold” and an average target price of $1.69.
Shares of Ocera Therapeutics (NASDAQ OCRX) opened at $1.77 on Monday. Ocera Therapeutics has a 1 year low of $0.52 and a 1 year high of $2.95.
Ocera Therapeutics (NASDAQ:OCRX) last issued its quarterly earnings data on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.24). analysts forecast that Ocera Therapeutics will post -0.93 earnings per share for the current fiscal year.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.